These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32532074)

  • 21. SWATH-Proteomics of Ibrutinib's Action in Myeloid Leukemia Initiating Mutated G-CSFR Signaling.
    Dwivedi P; Chutipongtanate S; Muench DE; Azam M; Grimes HL; Greis KD
    Proteomics Clin Appl; 2020 Sep; 14(5):e1900144. PubMed ID: 32319217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.
    Benner B; Carson WE
    J Hematol Oncol; 2021 Jan; 14(1):15. PubMed ID: 33441177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemoproteomic Profiling of an Ibrutinib Analogue Reveals its Unexpected Role in DNA Damage Repair.
    Ye Z; Wang Y; Wu H; Song T; Li X; Liu Q; Wang C
    Chembiochem; 2021 Jan; 22(1):129-133. PubMed ID: 32979005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
    Kriegsmann K; Kriegsmann M; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective.
    Brullo C; Villa C; Tasso B; Russo E; Spallarossa A
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of effector B cells by ibrutinib in systemic sclerosis.
    Einhaus J; Pecher AC; Asteriti E; Schmid H; Secker KA; Duerr-Stoerzer S; Keppeler H; Klein R; Schneidawind C; Henes J; Schneidawind D
    Arthritis Res Ther; 2020 Mar; 22(1):66. PubMed ID: 32228672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms.
    Al-Toubah T; Schell MJ; Cives M; Zhou JM; Soares HP; Strosberg JR
    Neuroendocrinology; 2020; 110(5):377-383. PubMed ID: 31357193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells.
    Kong W; Sender S; Taher L; Villa-Perez S; Ma Y; Sekora A; Ruetgen BC; Brenig B; Beck J; Schuetz E; Junghanss C; Nolte I; Murua Escobar H
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
    Wei L; Su YK; Lin CM; Chao TY; Huang SP; Huynh TT; Jan HJ; Whang-Peng J; Chiou JF; Wu AT; Hsiao M
    Oncotarget; 2016 Oct; 7(43):69961-69975. PubMed ID: 27564106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy.
    Sun SH; Angell CD; Savardekar H; Sundi D; Abood D; Benner B; DiVincenzo MJ; Duggan M; Choueiry F; Mace T; Trikha P; Lapurga G; Johnson C; Carlson EJ; Chung C; Peterson BR; Lianbo Yu ; Zhao J; Kendra KL; Carson WE
    Cancer Immunol Immunother; 2023 Nov; 72(11):3461-3474. PubMed ID: 37528320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
    Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
    Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
    Feng Y; Duan W; Cu X; Liang C; Xin M
    Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
    Wang Y; Zhang LL; Champlin RE; Wang ML
    Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations.
    Carda JP; Santos L; Mariz JM; Monteiro P; Gonçalves HM; Raposo J; Gomes da Silva M
    Hematology; 2021 Dec; 26(1):785-798. PubMed ID: 34605364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
    Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
    Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
    da Cunha-Bang C; Niemann CU
    Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.
    Lucas F; Woyach JA
    Target Oncol; 2019 Apr; 14(2):125-138. PubMed ID: 30927175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
    Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targets for Ibrutinib Beyond B Cell Malignancies.
    Berglöf A; Hamasy A; Meinke S; Palma M; Krstic A; Månsson R; Kimby E; Österborg A; Smith CI
    Scand J Immunol; 2015 Sep; 82(3):208-17. PubMed ID: 26111359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.